Natalia Bielicka

Dr. Natalia Bielicka

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2021 in Small
Verified
Journal Article
Closed access
ŁSŁukasz Suprewicz
Łukasz Suprewicz
MSMaxx Swoger
Maxx Swoger
SGSarthak Gupta
Sarthak Gupta
EPEwelina Piktel
Ewelina Piktel
FBFitzroy J. Byfield
Fitzroy J. Byfield
APAlison E. Patteson
Alison E. Patteson

13 January 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
NBNatalia Bielicka
Natalia Bielicka
AGAnna Gromotowicz-Popławska
Anna Gromotowicz-Popławska
Michał TomczykMichał Tomczyk
Michał Tomczyk
ECEwa Chabielska
Ewa Chabielska
The hemostasis system is often affected by complications associated with cardiovascular diseases, which results in thromboembolic events. Compounds of plant origin and plant extracts are considered as a promising source of substances that could modulate the functioning of the hemostasis system and thus reduce the risk of thromboembolism. Among them, tannins, which are plant-origin compounds with potential effects in hemostasis, deserve a special mention. This paper describes the hemostasis-modifying ability of three groups of tannins, namely ellagitannins, gallotannins, and procyanidins. The review highlights the desirable as well as undesirable influence of tannins on specific components of hemostasis, namely platelets, coagulation system, fibrinolysis system, and endothelium, and the multidirectional effect of these compounds on the thrombotic process. Studies performed under normal and pathological conditions such as diabetes or hypercoagulation are described, and the pathophysiology-dependent action of tannins is also highlighted. Most of the studies presented in the paper were performed in vitro, and due to the low bioavailability of tannins more studies should be conducted in the future to understand their actual activity in vivo.

19 July 2017 in Toxins
Verified
Journal Article
Open access
PDF file
MKMałgorzata Karbowska
Małgorzata Karbowska
TKTomasz W. Kaminski
Tomasz W. Kaminski
NBNatalia Bielicka
Natalia Bielicka
TMTomasz Misztal
Tomasz Misztal
TRTomasz Rusak
Tomasz Rusak
Dariusz PawlakDariusz Pawlak
Dariusz Pawlak
Chronic kidney disease (CKD) patients are at high risk for thrombotic events. Indoxyl sulfate (IS) is one of the most potent uremic toxins that accumulates during CKD. Even though IS is associated with an increased risk for cardiovascular disease, its impact on thrombotic events still remains not fully understood. The purpose of the study was to evaluate the direct effect of IS on thrombotic process. We examined the impact of acute exposure to IS on thrombus development induced by electric current in Wistar rats, intravital thrombus formation after laser-induced injury in the mice endothelium, coagulation profile, clot formation dynamics, platelet aggregations, and erythrocyte osmotic resistance. IS doses: 10, 30 and 100 mg/kg body weight (b.w.) increased weight of thrombus induced by electric current in dose-dependent manner (p < 0.001). Furthermore, two highest IS doses increased laser-induced thrombus formation observed via confocal system (increase in fluorescence intensity and total thrombus area (p < 0.01)). Only the highest IS dose decreased clotting time (p < 0.01) and increased maximum clot firmness (p < 0.05). IS did not affect blood morphology parameters and erythrocyte osmotic resistance, but augmented collagen-induced aggregation. Obtained data indicate that IS creates prothrombotic state and contributes to more stable thrombus formation. Thus, we concluded that IS may be one of crucial uremic factors promoting thrombotic events in CKD patients.

1 September 2019 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
TMTomasz Misztal
Tomasz Misztal
AGAgata Golaszewska
Agata Golaszewska
MTMaria Magdalena Tomasiak-Lozowska
Maria Magdalena Tomasiak-Lozowska
MIMarta Iwanicka
Marta Iwanicka
NBNatalia Bielicka
Natalia Bielicka
TRTomasz Rusak
Tomasz Rusak

29 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Ewelina PiktelEwelina Piktel
Ewelina Piktel
IOIlona Oscilowska
Ilona Oscilowska
ŁSŁukasz Suprewicz
Łukasz Suprewicz
JDJoanna Depciuch
Joanna Depciuch
NBNatalia Bielicka
Natalia Bielicka
RBRobert Bucki
Robert Bucki
Gold nanoparticles-assisted delivery of antineoplastics into cancerous cells is presented as an effective approach for overcoming the limitations of systemic chemotherapy. Although ceragenins show great potential as anti-cancer agents, in some tumors, effective inhibition of cancer cells proliferation requires application of ceragenins at doses within their hemolytic range. For the purpose of toxicity/efficiency ratio control, peanut-shaped gold nanoparticles (AuP NPs) were functionalized with a shell of ceragenin CSA-131 and the cytotoxicity of AuP@CSA-131 against ovarian cancer SKOV-3 cells and were then analyzed. In vivo efficiency of intravenously and intratumorally administered CSA-131 and AuP@CSA-131 was examined using a xenograft ovarian cancer model. Serum parameters were estimated using ELISA methods. Comparative analysis revealed that AuP@CSA-131 exerted stronger anti-cancer effects than free ceragenin, which was determined by enhanced ability to induce caspase-dependent apoptosis and autophagy processes via reactive oxygen species (ROS)-mediated pathways. In an animal study, AuP@CSA-131 was characterized by delayed clearance and prolonged blood circulation when compared with free ceragenin, as well as enhanced anti-tumor efficiency, particularly when applied intratumorally. Administration of CSA-131 and AuP@CSA-131 prevented the inflammatory response associated with cancer development. These results present the possibility of employing non-spherical gold nanoparticles as an effective nanoplatform for the delivery of antineoplastics for the treatment of ovarian malignancy.

31 December 2025 in Cells
Verified
Journal Article
Open access
PDF file
MBMagdalena Bruzgo-Grzybko
Magdalena Bruzgo-Grzybko
IKIzabela Suwda Kalita
Izabela Suwda Kalita
AOAdam Jan Olichwier
Adam Jan Olichwier
NBNatalia Bielicka
Natalia Bielicka
ECEwa Chabielska
Ewa Chabielska
AGAnna Gromotowicz-Poplawska
Anna Gromotowicz-Poplawska
Molecular imaging in preclinical research using PET and SPECT has become a key component of contemporary biomedicine, enabling noninvasive, quantitative, and longitudinal assessment of biological processes in vivo. Rapid technological progress, including advances in detector design, readout electronics, reconstruction algorithms, and multimodal integration, has substantially improved spatial resolution, sensitivity, and quantitative accuracy, thereby enhancing the translational value of animal models. PET and SPECT enable precise characterization of metabolic, molecular, and functional alterations across a wide range of diseases including cancer, cardiovascular disorders, neurodegeneration, and inflammation. Radiopharmaceuticals targeting diverse biological pathways, combined with PET and SPECT systems, allow comprehensive and physiologically relevant evaluation of disease mechanisms and therapeutic responses. Despite these significant advances, important challenges remain, including limitations in quantitative precision, partial-volume effects and inter-laboratory variability in experimental protocols. An additional limitation is the lack of globally standardized quality-control and calibration procedures tailored to preclinical imaging systems. Emerging multimodal imaging platforms and high-fidelity disease models, such as genetically engineered rodents, large animals, and zebrafish, continue to enhance reproducibility, biological relevance, and translational potential. This review summarizes the development, capabilities, and limitations of preclinical PET and SPECT imaging, highlighting their expanding role in advancing molecular diagnostics, radiopharmaceutical development, and translational medicine in both preclinical studies and early-phase clinical research.